Aspira Pathlab & Diagnostics is engaged within the business of running, owning, managing, and administering nosology Centers. The principal activities of the corporate include pathology investigation services, radiology investigation services and different connected health care services at Diagnostic Centres in urban centers.
About Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & medical specialty Ltd. was incorporated within the year 1973. Its today’s share worth is43.9. Its current market capitalization stands at Rs 45.19 Cr. within the latest quarter, the company has a reportable income of Rs. 84.16 metallic element and Total financial gain of Rs.87.04 Cr.
| Website | https://www.aspiradiagnostics.com/ |
| CMP | 43.9 INR |
Since its beginning, Aspira was selected to be at the forefront of comprehensive reliance on technological automation to supply wide-ranging diagnostic services that assist in mapping a patient’s entire aid journey. With the digital universe imploding onto a telephone screen.
AspiraHealth app, be it booking appointments and ordering tests reception, or observance check results and accessing one’s complete diagnostic history – everything is currently doable with a click of a button. Aspira can currently with pride it meets lifestyle through advanced technology.
•During the Financial Year 2019-20, the paid-up equity share capital of the Company has been increased
•Company will be expanding its area of operation & conducting more tests which will generate more revenue leading to more cash profit.
•Develop online presence together with a sharper focus on a home collection of samples to drive customer convenience •Associate with local labs that are threatened by the presence of collection centers of large labs
Financial Results (Year ended FY 20-21)
The company has reported a total income of Rs.15.40 crores during the 12 months period ended March 31, 2021, as compared to Rs.8.70 crores during the 12 months period ended March 31, 2020.
The company has posted a net profit of Rs.1.38 crores for the 12 months period ended March 31, 2021, as against a net profit of Rs 4.24 crores for the 12 months period ended March 31, 2020.
The company has reported EPS of Rs.1.34 for the 12 months period ended March 31, 2021, as compared to Rs. 4.56 for the 12 months period ended March 31, 2020.
The Company gave 2943000 value portions of Rs. 10 each at an issue cost of Rs. 17 per share on a particular premise to advertisers and a gathering of key financial backers not shaping the piece of the advertiser. The portion was made on nineteenth November 2016 and posting and exchanging endorsement is anticipated. The settled up capital as of 31st March 2017 was 5193000 value portions of Rs. 10 each.
The Company has changed its item proviso on tenth August 2016 its current name was changed on 16 November 2016 and the enlisted office of the organization was moved from State of West Bengal to the State of Maharashtra vide request dated eighteenth November 2016 and organization again moved its enrolled office inside the city furthest reaches of Mumbai on seventeenth March 2017.
| Capitalization | 45.2 Crore |  |
| Sales Increasing past 3 Years | Yes,51.7 % | |
| Profit Increasing past 3 Years | Yes, 31.0 % | |
| Durable Competitive Advantage | Yes | |
| Face Value | ₹ 10.0 | |
| ROE | 21.6 % | |
| Debt Equity Ratio | 20.2 | |
PE Ratio | 11.2 | |
PB Ratio | 5X |  |
| Intrinsic Value Discount | 82.6 % | |
| Promoter Holding & Increase | 36.2 % | |
| Multibagger Returns | 300-500% 5 Year | |
Positives
•During the Financial Year 2019-20, the paid-up equity share capital of the Company has been increased
•Company will be expanding its area of operation & conducting more tests which will generate more revenue leading to more cash profit.
•Develop online presence together with a sharper focus on the home collection of samples to drive customer convenience
•Associate with local labs that are threatened by the presence of collection centers of large labs
Negatives
•Competition and pricing
•Many small labs come into the market every year. This puts pressure on the pricing of established players since they have much larger overheads.
•The impact of COVID-19 on the Financial Statements of the Company, has been badly affected the company
Conclusion
In this section, we usually try to help investors determine whether Aspira Pathlab & Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aspira Pathlab & Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.